ROIVANT SCIENCES LTD

QVT Financial LP’s June 2026 sell‑off of 1.3 m Roivant shares signals strategic rebalancing, not a loss, as the stock stays below its 52‑week high.

ROIVANT insider buys: CEO Eric Venker’s 200k-share purchase at $34.06 signals confidence in the company’s high‑growth pipeline, but frequent Rule 10b5‑1 moves hint at potential volatility for investors.

Investor insights on Roivant Sciences insider moves: Venker’s strategic selling and buying around $32 shows liquidity plans amid bullish growth and promising trial data.

Explore how Roivant Sciences’ CEO’s buy‑sell‑exercise strategy balances liquidity with long‑term stake, and what it means for investors.

Roivant insider moves show routine vesting, not distress—Oren Ilan’s share activity confirms long‑term confidence amid a solid pipeline and upside potential.

Epperly Melissa B’s recent insider purchase signals steady confidence in Roivant Sciences, hinting at potential upside as the company advances its oncology pipeline.

Roivant insider sales reveal cautious valuation signals—an insider sold 160k shares at $27.70, hinting at future funding moves while the stock’s P/E stays negative.

Roivant Sciences CEO’s March 30, 2026 insider trade: CVAR conversion, share sales, and liquidity strategy—insider confidence signals a cautious but optimistic outlook.

Roivant’s CEO converts CVARs into 97k shares, signaling insider confidence and potential upside amid a $18B market cap.

Insider trading by Fitzgerald Meghan at Roivant shows a “buy low, sell high” pattern tied to positive Phase 3 brepocitinib data, hinting at a short‑term rally.